{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:50:42Z","timestamp":1791330642481,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":96,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011305","name":"Comprehensive Cancer Center, University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["5P30CAO13148-47"],"award-info":[{"award-number":["5P30CAO13148-47"]}],"id":[{"id":"10.13039\/100011305","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["1RO1CA294647- 01"],"award-info":[{"award-number":["1RO1CA294647- 01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) growth and metastasis are influenced by the tumor microenvironment (TME), which includes immune cells, endothelial cells, macrophages, and cancer-associated fibroblasts (CAFs). Since the novel integrin-targeted cytotoxin ProAgio can inhibit activated CAFs and endothelial cells, we investigated its combination with standard of care chemotherapies in genetically engineered mouse (GEM) and orthotopic murine models of PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We established metastatic murine KPC-Ganji &amp; Bassel-Luc (mKPC-GB-Luc) cell lines and validated them using bulk RNA sequencing. Two in vivo orthotopic mouse model were used to evaluate ProAgio with chemotherapy. mKPC-GB-Luc was used to evaluate the 5FU, oxaliplatin, and irinotecan (FOI combination), and KPC-ML1-Luc was used to evaluate the gemcitabine, nab-paclitaxel (GPTx combination). Immunohistochemistry was used to measure integrin \u03b23, E-cadherin, and HIF-1\u03b1. Hypoxia was evaluated using pimonidazole. Stem cells, CAFs, and immune cell subtypes were quantified by flow cytometry. We evaluated the combination of ProAgio plus gemcitabine in a KPC genetically engineered mouse model (KPC GEM). Two sets of KPC GEM were developed. The first set was used for a survival study. The second set was terminated early and tumors were used for single-cell RNA seq and sequential multiplex immunofluorescence (COMET).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the chemo regimen (GPTx or FOI), ProAgio, or sham, the combination of ProAgio plus chemo significantly modulated the TME, reduced tumor weight, reduced hypoxia, and eliminated metastasis to the lungs and liver. The combination of ProAgio and gemcitabine increased overall survival in KPC GEM mice compared with either treatment alone. Single-cell RNA sequencing, flow cytometry, immunofluorescence, immunohistochemistry, and COMET analyses demonstrated that ProAgio plus chemotherapy reprogrammed the PDAC-TME by changing activated CAFs toward a qCAFs (quiescent CAFs), macrophages from protumor to proinflammatory polarization, and activating natural killer (NK) cells, CD4\u207a, and CD8\u207a T cells. Combination therapy inhibited PDAC stemness. ProAgio-treated CAFs in vitro exhibited reduced secretion of glycine and cysteine, vital metabolites that support stemness and tumor progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results confirm the novel mechanism of action of ProAgio, which includes reducing hypoxia and modulating TME. The current data provide evidence for potentiation of chemotherapy efficacy by ProAgio.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-026-02725-3","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:04:21Z","timestamp":1783073061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-5234","authenticated-orcid":false,"given":"Ganji Purnachandra","family":"Nagaraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Sarvesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Chakra","family":"Turaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhana Sekhar Reddy","family":"Bandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Satyanarayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falguni","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvika","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Akce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel F.","family":"El-Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2725_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10.","journal-title":"CA Cancer J Clin"},{"key":"2725_CR2","doi-asserted-by":"crossref","unstructured":"Maddipati R. Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention. J Clin Investig. 2025;135:e191943.","DOI":"10.1172\/JCI191943"},{"key":"2725_CR3","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1021\/acs.molpharmaceut.4c00329","volume":"21","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Ma Y, Sheng J, Ma Y, Ding J, Zhou W. Breaking down barriers in drug delivery by stromal remodeling approaches in pancreatic cancer. Mol Pharm. 2024;21:3764\u201376.","journal-title":"Mol Pharm"},{"key":"2725_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1158\/2767-9764.CRC-24-0491","volume":"5","author":"C Wu","year":"2025","unstructured":"Wu C, Von Schalscha T, Sansanwal D, Qian C, Jiang Q, Shepard RM, Wettersten HI, McCormack SJ, Weis SM, Cheresh DA. Targeting pancreatic cancer cell stemness by blocking fibronectin-binding integrins on cancer-associated fibroblasts. Cancer Res Commun. 2025;5:195\u2013208.","journal-title":"Cancer Res Commun"},{"key":"2725_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1201\/9781003224921","volume-title":"The Tumor Stroma Biology and Therapeutics","author":"Kunal Pednekar","year":"2022","unstructured":"Pednekar K, Heinrich MA, Prakash J. Role of integrins in the tumor stroma. The Tumor Stroma. Jenny Stanford Publishing. 2022;233\u201386. https:\/\/doi.org\/10.1201\/9781003224921.","edition":"1"},{"key":"2725_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s00259-021-05595-7","volume":"50","author":"R Nakamoto","year":"2022","unstructured":"Nakamoto R, Ferri V, Duan H, Hatami N, Goel M, Rosenberg J, Kimura R, Wardak M, Haywood T, Kellow R. Pilot-phase PET\/CT study targeting integrin \u03b1v\u03b26 in pancreatic cancer patients using the cystine-knot peptide\u2013based 18F-FP-R01-MG-F2. Eur J Nucl Med Mol Imaging. 2022;50:184\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2725_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12964-023-01264-4","volume":"21","author":"S Li","year":"2023","unstructured":"Li S, Sampson C, Liu C, Piao H-l, Liu H-X. Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities. Cell Communication Signal. 2023;21:266.","journal-title":"Cell Communication Signal"},{"key":"2725_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2021.12.025","volume":"528","author":"P Nan","year":"2022","unstructured":"Nan P, Dong X, Bai X, Lu H, Liu F, Sun Y, Zhao X. Tumor-stroma TGF-\u03b21-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin \u03b1v\u03b23\/CD36-mediated activation of the MAPK pathway. Cancer Lett. 2022;528:59\u201375.","journal-title":"Cancer Lett"},{"key":"2725_CR9","doi-asserted-by":"crossref","unstructured":"Guo D-y, Chen Z-h, Fu Y-f, Li Y-y, Chen M-n, Wu J-j, Yuan Z-d, Ye J-X, Li X. Yuan F-l: Cilengitide inhibits osteoclast adhesion through blocking the \u03b1v\u03b23-mediated FAK\/Src signaling pathway. Heliyon. 2023;9:e17841.","DOI":"10.1016\/j.heliyon.2023.e17841"},{"key":"2725_CR10","doi-asserted-by":"crossref","unstructured":"Campos AD, Shepard RM, Ortega Z, Heumann I, Wilke AE, Nam A, Cable C, Kouhmareh K, Klemke R, Mattson NM. A STAT3\/integrin axis accelerates pancreatic cancer initiation and progression. Cell Rep. 2025;44:116010.","DOI":"10.1016\/j.celrep.2025.116010"},{"key":"2725_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jcmgh.2020.08.004","volume":"11","author":"RC Turaga","year":"2021","unstructured":"Turaga RC, Sharma M, Mishra F, Krasinskas A, Yuan Y, Yang JJ, Wang S, Liu C, Li S, Liu Z-R. Modulation of cancer-associated fibrotic stroma by an integrin \u03b1v\u03b23 targeting protein for pancreatic cancer treatment. Cell Mol Gastroenterol Hepatol. 2021;11:161\u201379.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2725_CR12","doi-asserted-by":"publisher","first-page":"11675","DOI":"10.1038\/ncomms11675","volume":"7","author":"RC Turaga","year":"2016","unstructured":"Turaga RC, Yin L, Yang JJ, Lee H, Ivanov I, Yan C, Yang H, Grossniklaus HE, Wang S, Ma C. Rational design of a protein that binds integrin \u03b1v\u03b23 outside the ligand binding site. Nat Commun. 2016;7:11675.","journal-title":"Nat Commun"},{"key":"2725_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s42003-021-02611-2","volume":"4","author":"RC Turaga","year":"2021","unstructured":"Turaga RC, Satyanarayana G, Sharma M, Yang JJ, Wang S, Liu C, Li S, Yang H, Grossniklaus H, Farris AB. Targeting integrin \u03b1v\u03b23 by a rationally designed protein for chronic liver disease treatment. Commun Biology. 2021;4:1087.","journal-title":"Commun Biology"},{"key":"2725_CR14","doi-asserted-by":"publisher","first-page":"e20200712","DOI":"10.1084\/jem.20200712","volume":"218","author":"M Sharma","year":"2021","unstructured":"Sharma M, Turaga RC, Yuan Y, Satyanarayana G, Mishra F, Bian Z, Liu W, Sun L, Yang J, Liu Z-R. Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC. J Exp Med. 2021;218:e20200712.","journal-title":"J Exp Med"},{"key":"2725_CR15","doi-asserted-by":"publisher","first-page":"e008086","DOI":"10.1136\/jitc-2023-008086","volume":"12","author":"NK Horvat","year":"2024","unstructured":"Horvat NK, Karpovsky I, Phillips M, Wyatt MM, Hall MA, Herting CJ, Hammons J, Mahdi Z, Moffitt RA, Paulos CM. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. J Immunother Cancer. 2024;12:e008086.","journal-title":"J Immunother Cancer"},{"key":"2725_CR16","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/s41588-024-01914-4","volume":"56","author":"AM Khaliq","year":"2024","unstructured":"Khaliq AM, Rajamohan M, Saeed O, Mansouri K, Adil A, Zhang C, Turk A, Carstens JL, House M, Hayat S. Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity. Nat Genet. 2024;56:2455\u201365.","journal-title":"Nat Genet"},{"key":"2725_CR17","doi-asserted-by":"publisher","first-page":"7815","DOI":"10.1038\/s41467-025-63083-0","volume":"16","author":"D Dong","year":"2025","unstructured":"Dong D, Zhou Z, Zhu M, Hou Z, Chen M, Gong J, Zhao X, Yan A, Liang H, Yin Y. STN1 facilitates metastasis by promoting transcription of EMT-activator ZEB1 in pancreatic cancer. Nat Commun. 2025;16:7815.","journal-title":"Nat Commun"},{"key":"2725_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","volume":"24","author":"L P\u00e9rez-Guti\u00e9rrez","year":"2023","unstructured":"P\u00e9rez-Guti\u00e9rrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023;24:816\u201334.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2725_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579\u201396.","journal-title":"J Exp Med"},{"key":"2725_CR20","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9:1102\u201323.","journal-title":"Cancer Discov"},{"key":"2725_CR21","doi-asserted-by":"crossref","unstructured":"Nagaraju GP, Saddala MS, Foote JB, Khaliq AM, Masood A, Golivi Y, Bandi DSR, Sarvesh S, Reddy SP, Switchenko J. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Cell Rep Med. 2025;6:101881.","DOI":"10.1016\/j.xcrm.2024.101881"},{"key":"2725_CR22","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1158\/0008-5472.CAN-22-2316","volume":"83","author":"S Schw\u00f6rer","year":"2023","unstructured":"Schw\u00f6rer S, Cimino FV, Ros M, Tsanov KM, Ng C, Lowe SW, Carmona-Fontaine C, Thompson CB. Hypoxia potentiates the inflammatory fibroblast phenotype promoted by pancreatic cancer cell\u2013derived cytokines. Cancer Res. 2023;83:1596\u2013610.","journal-title":"Cancer Res"},{"key":"2725_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41389-022-00434-2","volume":"11","author":"AM Mello","year":"2022","unstructured":"Mello AM, Ngodup T, Lee Y, Donahue KL, Li J, Rao A, Carpenter ES, Crawford HC, di Pasca M, Lee KE. Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer. Oncogenesis. 2022;11:56.","journal-title":"Oncogenesis"},{"key":"2725_CR24","doi-asserted-by":"crossref","unstructured":"Sazeides C, Le A. Metabolic relationship between cancer-associated fibroblasts and cancer cells. The heterogeneity of cancer metabolism. Springer International Publishing Cham, 2021;1311:189\u2013204.","DOI":"10.1007\/978-3-030-65768-0_14"},{"key":"2725_CR25","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41575-021-00431-7","volume":"18","author":"J Encarnacion-Rosado","year":"2021","unstructured":"Encarnacion-Rosado J, Kimmelman AC. Harnessing metabolic dependencies in pancreatic cancers. Nat Reviews Gastroenterol Hepatol. 2021;18:482\u201392.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"2725_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target therapy. 2023;8:70.","journal-title":"Signal Transduct Target therapy"},{"key":"2725_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41419-023-06032-3","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang J, Liu Y, Liu S. The role of epithelial-mesenchymal transition and autophagy in pancreatic ductal adenocarcinoma invasion. Cell Death Dis. 2023;14:506.","journal-title":"Cell Death Dis"},{"key":"2725_CR28","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1089\/ars.2011.4280","volume":"16","author":"E Giannoni","year":"2012","unstructured":"Giannoni E, Parri M, Chiarugi P. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid Redox Signal. 2012;16:1248\u201363.","journal-title":"Antioxid Redox Signal"},{"key":"2725_CR29","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/15384047.2014.1003005","volume":"16","author":"JD Sun","year":"2015","unstructured":"Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, Bhupathi D, Ruprell AS, Hart CP. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther. 2015;16:438\u201349.","journal-title":"Cancer Biol Ther"},{"key":"2725_CR30","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1186\/s12967-025-06778-8","volume":"23","author":"Q Li","year":"2025","unstructured":"Li Q, Yang C, Li J, Wang R, Min J, Song Y, Su H. The type I collagen paradox in PDAC progression: microenvironmental protector turned tumor accomplice. J Translational Med. 2025;23:744.","journal-title":"J Translational Med"},{"key":"2725_CR31","doi-asserted-by":"publisher","first-page":"21197","DOI":"10.1074\/jbc.M113.484576","volume":"288","author":"S Arora","year":"2013","unstructured":"Arora S, Bhardwaj A, Singh S, Srivastava SK, McClellan S, Nirodi CS, Piazza GA, Grizzle WE, Owen LB, Singh AP. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor \u03baB-and hypoxia-inducible factor 1\u03b1-mediated up-regulation of CXCR4. J Biol Chem. 2013;288:21197\u2013207.","journal-title":"J Biol Chem"},{"key":"2725_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trsl.2018.12.008","volume":"207","author":"MY Abdalla","year":"2019","unstructured":"Abdalla MY, Ahmad IM, Rachagani S, Banerjee K, Thompson CM, Maurer HC, Olive KP, Bailey KL, Britigan BE, Kumar S. Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition. Translational Res. 2019;207:56\u201369.","journal-title":"Translational Res"},{"key":"2725_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","volume":"29","author":"R Rebelo","year":"2023","unstructured":"Rebelo R, Xavier CP, Giovannetti E, Vasconcelos MH. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol Med. 2023;29:439\u201353.","journal-title":"Trends Mol Med"},{"key":"2725_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13046-023-02934-4","volume":"42","author":"R Melchionna","year":"2023","unstructured":"Melchionna R, Trono P, Di Carlo A, Di Modugno F, Nistic\u00f2 P. Transcription factors in fibroblast plasticity and CAF heterogeneity. J Experimental Clin Cancer Res. 2023;42:347.","journal-title":"J Experimental Clin Cancer Res"},{"key":"2725_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu C-C, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719\u201334.","journal-title":"Cancer Cell"},{"key":"2725_CR36","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735\u201347.","journal-title":"Cancer Cell"},{"key":"2725_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nrgastro.2014.97","volume":"11","author":"I Leake","year":"2014","unstructured":"Leake I. Surprising role for fibrosis. Nat Reviews Gastroenterol Hepatol. 2014;11:396\u2013396.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"2725_CR38","doi-asserted-by":"publisher","first-page":"58649","DOI":"10.18632\/oncotarget.10765","volume":"7","author":"V Longo","year":"2016","unstructured":"Longo V, Brunetti O, Gnoni A, Cascinu S, Gasparini G, Lorusso V, Ribatti D, Silvestris N. Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Oncotarget. 2016;7:58649.","journal-title":"Oncotarget"},{"key":"2725_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.18632\/genesandcancer.171","volume":"9","author":"A Cannon","year":"2018","unstructured":"Cannon A, Thompson C, Hall BR, Jain M, Kumar S, Batra SK. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Genes cancer. 2018;9:78.","journal-title":"Genes cancer"},{"key":"2725_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62:112\u201320.","journal-title":"Gut"},{"key":"2725_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fphar.2013.00056","volume":"4","author":"A Tamburrino","year":"2013","unstructured":"Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol. 2013;4:56.","journal-title":"Front Pharmacol"},{"key":"2725_CR42","doi-asserted-by":"crossref","unstructured":"Sazeides C, Le A. Metabolic relationship between cancer-associated fibroblasts and cancer cells. Heterogeneity Cancer Metabolism. 2018;1063:149\u201365.","DOI":"10.1007\/978-3-319-77736-8_11"},{"key":"2725_CR43","unstructured":"Ortiz AG. Assessing the phenotype of pancreatic cancer stem cells under adaptation to serine and glycine deficiency. Effects on metabolic plasticity and immune evasive properties. 2024;1\u201326. Undergraduate thesis."},{"key":"2725_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/stmcls\/sxad017","volume":"41","author":"AO Ogunleye","year":"2023","unstructured":"Ogunleye AO, Nimmakayala RK, Batra SK, Ponnusamy MP. Metabolic rewiring and stemness: a critical attribute of pancreatic cancer progression. Stem Cells. 2023;41:417\u201330.","journal-title":"Stem Cells"},{"key":"2725_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aaw9872","volume":"368","author":"MA Badgley","year":"2020","unstructured":"Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee H-J, Purohit V, Sagalovskiy IR, Ma A, Kapilian J, Firl CE. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368:85\u20139.","journal-title":"Science"},{"key":"2725_CR46","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.7150\/thno.89805","volume":"14","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Fang S, Fan B, Xu K, Xu L, Wang L, Zhu L, Chen C, Wu R, Ni J. Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer. Theranostics. 2024;14:1683.","journal-title":"Theranostics"},{"key":"2725_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/cas.15609","volume":"114","author":"Y Yamamoto","year":"2023","unstructured":"Yamamoto Y, Kasashima H, Fukui Y, Tsujio G, Yashiro M, Maeda K. The heterogeneity of cancer-associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment. Cancer Sci. 2023;114:16\u201324.","journal-title":"Cancer Sci"},{"key":"2725_CR48","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-19-0454","volume":"79","author":"Y Mizutani","year":"2019","unstructured":"Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res. 2019;79:5367\u201381.","journal-title":"Cancer Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02725-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:03:56Z","timestamp":1791327836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02725-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2725"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02725-3","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"233"}}